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Abstract
Detergent insoluble inclusions of TDP-43 protein are hallmarks of the neuropathology in over 
90% of amyotrophic lateral sclerosis (ALS) cases and approximately half of frontotemporal 
dementia (FTLD-TDP) cases. In TDP-43 proteinopathy disorders, lesions containing aggregated 
TDP-43 protein are extensively post-translationally modified, with phosphorylated TDP-43 
(pTDP) being the most consistent and robust marker of pathological TDP-43 deposition. 
Abnormally phosphorylated TDP-43 has been hypothesized to mediate TDP-43 toxicity in many 
neurodegenerative disease models. To date several different kinases have been implicated in the 
genesis of pTDP, but no phosphatases have been shown to reverse pathological TDP-43 
phosphorylation. We have identified the phosphatase calcineurin as an enzyme binding to and 
catalyzing the removal of pathological C-terminal phosphorylation of TDP-43 in vitro. In C. 
elegans models of TDP-43 proteinopathy, genetic elimination of calcineurin results in 
accumulation of excess pTDP, exacerbated motor dysfunction, and accelerated neurodegenerative 
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changes. In cultured human cells, treatment with FK506 (tacrolimus), a calcineurin inhibitor, 
results in accumulation of pTDP species. Lastly, calcineurin co-localizes with pTDP in 
degenerating areas of the central nervous system in subjects with FTLD-TDP and ALS. Taken 
together these findings suggest calcineurin acts on pTDP as a phosphatase in neurons. 
Furthermore, patient treatment with calcineurin inhibitors may have unappreciated adverse 
neuropathological consequences.
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Introduction
Neuronal cytoplasmic and nuclear aggregates of TAR DNA binding protein 43 (TDP-43) are 
the major pathological lesion in ~90% of patients with amyotrophic lateral sclerosis (ALS) 
and ~50% of patients with frontotemporal lobar degeneration (FTLDTDP) [2, 46, 47]. Since 
the first report of TDP-43 positive aggregates in ALS and FTLDTDP, other 
neurodegenerative diseases have been reported to have TDP-43 aggregates as a secondary 
pathologic feature in a subset of cases. These include Alzheimer’s disease (AD), chronic 
traumatic encephalopathy, traumatic brain injury, progressive supranuclear palsy, 
corticobasal degeneration, argyrophilic grain disease, post-encephalitic parkinsonism, 
dementia with Lewy bodies, and Huntington’s disease [1, 15, 19, 35, 40, 44, 52, 57, 61]. 
TDP-43 pathology has been correlated with severity of cognitive impairment and rate of 
cognitive decline in AD [23, 24, 59]. Further, numerous familial ALS causing mutations 
have been identified in TARDBP, the gene coding for TDP-43 protein, indicating that 
abnormal TDP-43 is not merely a hallmark of neurodegeneration, but that pathological 
TDP-43 drives disease [25, 31, 50, 56, 58].
Pathological TDP-43 exhibits a variety of post-translational modifications not observed in 
healthy neurons, including ubiquitination, acetylation, SUMOylation, and phosphorylation 
[2, 10, 46, 53]. Of these post-translational modifications, abnormal phosphorylation of 
TDP-43 is the most consistent and robust neuropathological marker of ALS/FTLD [45]. 
Specific sites of phosphorylation have been mapped and characterized in disease. These 
pathological phosphorylation sites cluster in the C-terminus of the TDP-43 protein, 
predominantly at serines 409 and 410 (S409/410), although phosphorylation at S379, S403, 
and S404 also correlate with disease pathology [18, 45]. Phosphorylation at S409/410 has 
been shown to promote decreased TDP-43 protein turnover, increased TDP-43 stabilization, 
cellular mislocalization of TDP-43, protein aggregation, and neurodegeneration [3, 7, 18, 32, 
33, 62].
Several kinases have been identified that phosphorylate TDP-43, including CK1/2, CDC7, 
and TTBK1/2 [18, 33, 34]. These kinases may act in response to overlapping or unique sets 
of cellular or environmental triggers. Phosphatases catalyze the reversal of protein 
phosphorylation on their protein targets by removing phosphate groups from modified 
tyrosine, serine, and threonine residues. However, in the case of TDP-43, the specific 
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phosphatase(s) responsible for reversing pathological phosphorylation have yet to be 
identified. Here we show the phosphatase calcineurin binds and dephosphorylates TDP-43 at 
pathological sites S409/410. Calcineurin activity on TDP-43 prevents accumulation of toxic 
TDP-43 species preserving neuronal homeostasis.
Materials and Methods
Yeast two-hybrid screen
Bait plasmids were constructed in the pLexA-N vector. Wild-type or M337V TDP-43 amino 
acids 260-414 were inserted under control of the LexA promoter. Cultures of TDP-43 bait 
plasmid yeast were grown overnight at 30°C, brought to log phase the next day, and 
transformed with the Clontech Matchmaker Human Fetal Brain Library (1.3 mg/mL), a 
cDNA library in the pACT2 vector, resulting in 1.2×106 (Wild-type) or 8.2×106 (M337V) 
transformants. Transformants were plated on 150mm plates of SD minimal media lacking 
leucine, tryptophan, and histidine and containing 25mM 3-Amino-1,2,4-Triazole (3-AT) and 
grown at 30°C. Colonies were picked and grown in SD broth lacking tryptophan and 
leucine. The candidate prey plasmid from the matchmaker library was isolated, transformed 
and amplified in E. coli, re-isolated, and identified by sequencing from primers within the 
pACT2 backbone.
Yeast spotting assay
L40 Ura− yeast were grown overnight and brought to log phase in YPAD medium, then co-
transformed with combinations of LexA TDP-43(WT), (A315T), and (M337V) with the 
pACT2/ PPP3CC clone. pACT2/ MS2 was co-transformed as a negative control for PPP3CC 
interaction. Transformants were plated on SD minimal media lacking leucine and tryptophan 
and grown at 30°C. Colonies were isolated and grown in SD broth lacking tryptophan and 
leucine at 30°C overnight. One OD600 unit of yeast was collected, washed 3x in sterile 
water, diluted in series, then spotted on SD minimal media plates lacking leucine, 
tryptophan, and histidine with a titration series of 0, 5, 10, 15, 20, or 25 mM 3-AT. Images 
shown are at 10mM 3-AT after 6 days of growth.
In vitro dephosphorylation assays
Purified recombinant human calcineurin and calmodulin were purchased from Enzo 
Lifesciences (Catalog #s BML-SE325, BML-SE163). Phosphorylated TDP-43 was prepared 
by in vitro phosphorylation using recombinant CDC7 kinase and glutathione-bound GST-
TDP-43 fusion protein as previously described [33]. Dephosphorylation was carried out in 
dephosphorylation reaction buffer [50 mm HEPES, pH 7.2, 50 mM NaCl, 2 mM MnCl2, 1 
mM CaCl2, 1 mM DTT]. In an 40 μl reaction volume, approximately 400 units of 
Calcineurin and 1 μg of calmodulin were added to 2 μg of phosphorylated bead bound 
TDP-43 protein and incubated at 30°C for varying times up to 1 hour.
C. elegans strains and transgenics
Construction and characterization of TDP-43 transgenic (tg) strains used were described 
previously [32]. In brief, TDP-43 tg strains were generated by introducing familial ALS 
mutant human TDP-43 cDNAs driven by the pan neuronal snb-1 promoter 
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(Psnb-1::TDP-43) into the C. elegans genome. TDP-43 tg strains used were CK426: 
TDP-43(A315T), CK423: TDP-43(M337V), CK410: TDP-43(WT), and CK507: 
TDP-43(M337V SS/AA). tax-6(p657);TDP-43 tg and tax-6(ok2065);TDP-43 tg animals 
were obtained by crossing PR675 tax-6(p657) or RB1667 tax-6(ok2065) with CK426, 
CK410 and CK507. cnb-1(jh103);TDP-43 tg animals were obtained by crossing KJ300 
cnb-1(jh103) with CK423, CK410, and CK507.
Behavioral analysis
Assessments of C. elegans locomotion were carried out as previously described with minor 
modifications [32]. In brief, 15-20 animals were placed at the center of a 100mm plate of 5x 
concentrated peptone nematode growth media uniformly seeded with OP-50 bacteria. 
Animals were allowed to move freely for 30 minutes, and the radial distance traveled from 
the start point was recorded. Distance traveled was converted to micrometers per minute.
Neurodegeneration assays
Strains with GFP marked gamma-aminobutyric acid (GABA)-ergic motor neurons were 
generated by crossing tax-6(ok2065) with CK426, CK410, CK507, and the reporter strain 
EG1285 [Punc-47::GFP]. Animals were grown to day 1 adult. Living animals were 
immobilized on a 2% agarose pad with 0.01% sodium azide, and intact GABA-ergic neurons 
were scored under fluorescence microscopy on a DeltaVision Elite (GE, Issaquah, WA) 
imaging system using an Olympus 60x oil objective. Statistical significance was analyzed 
using Prism statistical software.
Cell culture
HEK 293 cells (from ATCC) were cultured under standard culture condition in Dulbecco’s 
modified Eagle medium (DMEM), 10% fetal bovine serum (FBS), penicillin (50 IU/ml)–
streptomycin (50 mg/ml). For induced pTDP assays, cells were treated with FK506 (Prograf, 
Astellas Pharma) for 1.5 hours before addition of 150μM ethacrynic acid (EA) to induce 
production of phosphorylated TDP-43. Cells were harvested 3 hours after addition of EA, 
washed in PBS, and snap frozen in liquid N2. For FK506 treatment alone, cells were 
incubated with the indicated concentrations of FK506 for 24 hours, harvested, washed in 
PBS, and snap frozen in liquid N2. For Ni2+ metal ion activation of calcineurin, cells were 
incubated with 500μM NiCl2 for 3 hours, then harvested, washed in PBS, and snap frozen in 
liquid N2. For immunofluorescence assays, cells were grown on poly-D-lysine coated round 
cover slips (Neuvitro), treated with 10μM FK506 for 1.5 hours, followed by addition of 
150μM EA for 3 hours. Cells were fixed in fresh 2% paraformaldehyde, followed by a 20 
minute incubation in citrate buffer (10mM sodium citrate, 0.05% Tween 20, pH 6.0) at 80°C, 
and a 5 minute incubation in 0.1% Triton X-100. Cells were then incubated with the 
monoclonal antibody anti-phospho-TDP-43 (pS409/410) (CosmoBio TIP-PTD-M01) at 
1:1000 dilution, with AlexaFluor 594 anti-mouse secondary antibody (Molecular Probes), 
followed by DAPI staining.
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Immunoblotting
Samples were loaded and resolved on precast 4-15% gradient SDS-PAGE gels and 
transferred to PVDF membrane as recommended by the manufacturer (Bio-Rad). On 
immunoblots, human TDP-43 was detected by anti-TDP-43 (Abcam ab57105). TDP-43 
phosphorylated at S409/S410 was detected by a monoclonal antibody anti-phospho TDP-43 
(pS409/410) (Cosmobio TIP-PTD-M01). C. elegans β-tubulin levels were measured using 
monoclonal antibody E7 (Developmental Studies Hybridoma Bank) as a loading control. 
Human calcineurin was detected using anti-calcineurin antibody (Abcam ab82325). 
Dilutions were: 1:5000 for all primary antibodies. HRP labeled goat anti-mouse IgG was the 
secondary antibody (Jackson ImmunoResearch) and used at a dilution of 1:5000.
Protein extraction
Total protein fractions were obtained by lysing samples in RAB high salt buffer by 
homogenization as previously described [17]. For extraction of insoluble TDP-43 protein 
aggregates, fractions were obtained using methods previously described for analysis of 
FTLD-U and ALS brain samples [46]. Briefly, packed worm or cell pellets were 
resuspended in twice the amount (w/v) of Low Salt buffer (LS: [10 mM Tris, 5 mM EDTA, 
10% Sucrose, pH 7.5]). Samples were completely lysed by sonication and homogenates 
centrifuged at 25,000 x g for 30 min. The supernatant constitutes the LS fraction. The pellet 
was re-extracted with non-ionic detergent containing buffer (TX: [10 mM Tris, 5 mM 
EDTA, 1% Triton X-100, 10% Sucrose, pH 7.5], centrifuged 20 min at 180,000 x g, with the 
supernatant constituting the TX fraction. The resulting pellet was extracted with ionic 
detergent containing buffer (SARK: [10 mM Tris, 5 mM EDTA, 1% Sarkosyl, 10% Sucrose, 
pH 7.5] and 180,000 x g for 20 minutes. The supernatant is the SARK fraction. The final 
pellet was solubilized in urea containing buffer (UREA: [30 mM Tris, 7M urea, 2M 
thiourea, 4% CHAPS, pH8.5]). All buffers contained Completetm Protease Inhibitor Cocktail 
(Roche) and 0.5 mM phenylmethylsulfonylfluoride to block proteolysis.
Post mortem human tissue
De-identified post-mortem brain tissue used in this study was determined to be exempt from 
IRB review by the VA Puget Sound Health Care System Human Research Protection 
Program Director on December 29, 2011. Tissue used for these studies was obtained from 
the University of Washington Alzheimer’s Disease Research Center brain bank (Seattle, 
WA), and the Indiana Alzheimer Disease Center brain bank (Indianapolis, IN), where 
consent for autopsy and permission for use of tissue in scientific experiments was obtained. 
FTLD-TDP (n = 10) and ALS (n= 2) cases were selected on the basis of having an autopsy-
confirmed diagnosis of FTLD and FTLD-related disorders or ALS. Control samples (n = 8) 
were from Center participants who were neurologically healthy, lacked pTDP or tau 
containing lesions, and were of a similar age. Neither cases nor controls showed 
neuropathologic changes of Lewy body accumulation, ischemic injury, or hemorrhage in 
consensus screening sections [20, 41].
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Immunohistochemistry and immunofluorescence analysis
Immunohistochemistry was performed on paraffin embedded frontal cortex and 
hippocampal sections from 10 FTLD-TDP cases and 8 normal control cases. Primary 
antibodies used were mouse monoclonal anti-Calcineurin A antibody CC-6 (Abcam, 1:500) 
and rat monoclonal anti-phospho TDP-43 409/410 (Antibody 1D3, gift of Manuela 
Neumann, 1:400). In order to minimize variability, sections from all cases (normal and 
affected subjects) were stained simultaneously for each antibody. Briefly, 5 μm sections 
were deparaffinized in xylene, rehydrated through graded alcohols, and an antigen retrieval 
step consisting of autoclaving sections in citrate buffer (1.8 mM citric acid/ 8.2 mM sodium 
citrate) was performed. Sections were treated for endogenous peroxidases with 3% hydrogen 
peroxide, blocked in 5% milk, incubated with primary antibody overnight at 4°C, followed 
by biotinylated secondary antibody for 45 minutes at room temperature. Finally, sections 
were incubated in an avidin-biotin complex (Vector’s Vectastain Elite ABC kit, Burlingame, 
CA) and the reaction product was visualized with 0.05% diaminobenzidine (DAB)/0.01% 
hydrogen peroxide in PBS. Nickel enhancement (DAB with 0.2% Ni) was utilized for 
phospho TDP-43 visualization. For double labeling experiments, sections were 
simultaneously immunostained with anti-phospho TDP-43 and calcineurin, while secondary 
antibody application and detection was performed consecutively. For double label 
immunofluorescence experiments on FTLD-TDP and ALS cases, AlexaFluor 488 goat anti-
mouse and AlexaFluor 594 goat anti-rat secondary antibodies (Molecular Probes) were used 
and autofluorescence was quenched with 0.1% Sudan Black. Primary antibodies were tested 
singly to confirm staining patterns and avoid misinterpretation of double label staining. 
Fluorescent secondary antibodies were validated for specificity using a spotted antibody 
assay (dot blot) and were confirmed to have no immunoreactivity on tissue in the absence of 
primary antibody. Colocalization plots for statistical analysis (Pearson’s coefficient of 
correlation) were generated using softWoRX 5.0 software (Applied Precision, Issaquah, 
WA). Colocalization analysis was performed on panel images taken using a 60x oil 
immersion objective.
Photomicrography and figure preparation
Immunohistochemistry photomicrographs were taken with a digital camera and imported 
into Adobe Photoshop for mounting. Fluorescent and immunofluorescent microscopy was 
performed on a Delta Vision microscope (Applied Precision, Issaquah, WA) using a 20X air 
or a 60x oil immersion objective, a sCMOS camera, and 2×2 binning. Image acquisition, 
deconvolution, and analysis were performed using softWoRx 5.0 software (GE, Issaquah, 
WA). To optimize visualization of staining or immunofluorescence, photomicrographs were 
modified, when necessary, by adjusting brightness and contrast.
Results
Calcineurin binds and dephosphorylates the phosphorylated C-terminus of TDP-43
TDP-43 protein contains distinct functional domains, including two RNA recognition 
motifs, nuclear localization and export signals, and a prion-like G-rich C-terminal domain 
important for protein-protein interactions (Fig. 1a). The C-terminus of TDP-43 is the site of 
the majority of ALS-causing mutations identified in human disease, indicating this region of 
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the protein may mediate pathological protein modifications and aggregation. 
Phosphorylation at the C-terminal serines 409 and 410 (S409/410) are a pathological 
signature of ALS, FTLD-TDP, and other TDP-43 proteinopathies.
To identify proteins that interact with the C-terminus of TDP-43, we performed a yeast two-
hybrid screen using human TDP-43 amino acids 260-414 as bait (Fig. 1a). We surveyed a 
human fetal brain library for TDP-43 C-terminus binding proteins. From this screen, we 
identified PPP3CC as a protein-protein interaction partner of both wild-type TDP-43 and 
familial ALS mutated TDP-43 (A315T, M337V) (Fig. 1b). PPP3CC is the catalytic subunit 
of protein phosphatase 3 heterodimer, better known as calcineurin [43]. Calcineurin is a 
Ca2+/calmodulin-dependent protein phosphatase highly expressed in the mammalian brain 
[29]. Calcineurin has been extensively studied, and has numerous regulatory roles impacting 
synaptic plasticity, membrane receptors, ion channels, neuritogenesis, and response to 
ischemia [5, 6, 42].
To test whether calcineurin can bind and dephosphorylate TDP-43 directly, we used an in 
vitro dephosphorylation assay incubating purified calcineurin with phosphorylated full-
length wild type TDP-43. We observed that TDP-43 was robustly dephosphorylated by 
calcineurin (Fig. 1c), demonstrating a functional enzyme/substrate relationship between 
calcineurin and TDP-43 phosphorylated at S409/410 (pTDP).
Calcineurin regulates pTDP levels in vivo in C. elegans
Given calcineurin’s observed activity on pTDP in vitro, it may regulate TDP-43 
phosphorylation levels in vivo. To test this hypothesis, we utilized a C. elegans model of 
ALS that expresses full-length human TDP-43 pan-neuronally. This model exhibits 
progressive age-dependent movement defects and neurodegeneration, as well as 
accumulation of insoluble phosphorylated, ubiquitinated, and C-terminal truncated species 
of TDP-43 [32]. The C. elegans calcineurin A homolog TAX-6 plays important roles in 
behavioral modulation, but knockout of worm tax-6 is viable [30]. We crossed two different 
genetic loss-of-function alleles of tax-6 to our TDP-43 transgenic animals and assayed 
changes in TDP-43 phosphorylation by immunoblot. In the absence of functional tax-6, we 
saw an increase in the amount of total and phosphorylated human TDP-43 in transgenic 
animals expressing either WT or fALS mutant A315T TDP-43 (Fig. 2a-e), consistent with a 
conserved role for calcineurin as a TDP-43 phosphatase. We and others have observed a link 
between total TDP-43 and pTDP levels; when pTDP is increased, total TDP-43 protein also 
increases [7, 26, 33, 62]. This may be due to changes in protein stability or pTDP’s blockade 
of normal TDP-43 protein degradation pathways.
In both mammals and C. elegans, the absence of calcineurin’s regulatory subunit results in 
greatly reduced catalytic activity [4, 54]. Therefore, we also tested the effect of a loss of 
function mutation in the calcineurin B regulatory subunit, cnb-1. We observed a similar 
increase in total TDP-43 and pTDP in both wild-type TDP-43(WT); cnb-1(−) and fALS 
mutant TDP-43(M337V); cnb-1(−) animals (Supplemental Fig. 1a-e). Consequently, 
decreasing calcineurin activity by depletion of either catalytic or regulatory subunits allows 
pTDP accumulation, as a result of its failure to dephosphorylate TDP-43.
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Detergent insoluble pTDP occurs in the neuronal inclusions of ALS and FTLDTDP. Our C. 
elegans TDP-43 transgenic animals also accumulate detergent insoluble TDP-43 [32]. To 
determine whether tax-6(−) promotes accumulation of insoluble pTDP, we treated 
TDP-43(A315T); tax-6(−) animals with sequential protein extractions with detergents of 
increasing solubilizing strengths. We observed that both pTDP and total TDP-43 accumulate 
in the sarkosyl-insoluble fraction, and loss of functional tax-6 increases insoluble TDP-43 
and pTDP (Fig. 2e). We also assayed TDP-43(M337V); cnb-1(−) animals, and saw a similar 
accumulation of insoluble pTDP and total TDP-43 (Supplemental Fig. 1e).
tax-6(−) animals move normally, while TDP-43 transgenic animals have obvious and 
progressive motor dysfunction leading to paralysis and death (Supplemental Fig. 1f, [32]). 
However, in TDP-43(WT); tax-6(−) and TDP-43(A315T); tax-6(−) animals, we observed 
dramatic exacerbation of the TDP-43 induced motor dysfunction relative to TDP-43 animals 
alone (Fig. 2h-i). cnb-1(−) animals are hyperactive relative to wild-type animals 
(Supplemental Fig. 1f); however, TDP-43(M337V); cnb-1(−) animals also displayed 
significantly worsened motor dysfunction (Supplemental Fig. 1g). To test whether the 
tax-6(−) enhancement of TDP-43 phenotypes is due to phosphorylation at S409/410, we 
crossed tax-6(−) or cnb-1(−) with TDP-43 animals containing non-phosphorylatable serine 
to alanine substitutions at S409/410 (SS/AA) in addition to M337V. We found that loss of 
tax-6 increased levels of total TDP-43 (Fig. 2f-g). However, neither TDP-43(M337V SS/
AA); tax-6(−) nor TDP-43(M337V SS/AA); cnb-1(−) animals have any enhancement of 
locomotion dysfunction (Fig. 2j and Supplemental Fig. 1h), indicating the synthetic toxicity 
of calcineurin loss-of-function and the TDP-43 transgene occurs through regulation of 
S409/410 phosphorylation and not through changes in levels of total TDP-43 protein.
Loss of calcineurin promotes TDP-43 mediated neurodegeneration in C. elegans
TDP-43 tg animals display degeneration of specific neuronal types with aging, including 
gamma-aminobutyric acid (GABA) positive inhibitory motor neurons [32]. Loss of 
calcineurin may promote neuronal dysfunction or increased neurodegeneration. C. elegans 
neuronal integrity can be assessed in vivo using a GABAergic D-type motor neuron reporter, 
Punc-47::GFP, which drives expression of GFP in all 19 D-type motor neurons [39]. To 
determine whether motor neurons are lost at a higher rate in TDP-43 tg; tax-6(−) animals, 
we scored intact GABAergic motor neurons in vivo using the fluorescent reporter. We found 
that although TDP-43(WT) animals alone did not exhibit significant neuronal loss at day 1 
of adulthood, TDP-43(WT); tax-6(−) animals lost an average of nearly 7% of total D-type 
GABAergic neurons. TDP-43(A315T) animals lost an average of 12%, but TDP-43(A315T); 
tax-6(−) animals lost 36% of GABAergic neurons (Fig. 3a-f). These animals also displayed 
dystrophic neurites, axonal defasciculation, and frank degeneration of axons (Supplemental 
Fig. 2). Therefore in C. elegans the loss of calcineurin promotes neuronal dysfunction and 
death. To test whether phosphorylation at S409/410 is necessary for tax-6 loss of function 
mediated neurodegeneration, we tested TDP-43(M337V SS/AA); tax-6(−) animals. These 
animals had no appreciable neurodegeneration and were identical to control animals without 
TDP-43 transgenes (Figure 3a). Taken together, the biochemical, behavioral, and imaging 
data above demonstrate calcineurin functions in vivo to regulate TDP-43 phosphorylation 
levels and subsequent neurotoxicity.
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Inhibition of calcineurin promotes accumulation of pTDP in human cells without altering 
TDP-43 RNA splicing functions
We have shown human calcineurin acts to directly dephosphorylate TDP-43 in vitro. Thus 
calcineurin may normally prevent the accumulation of pTDP in vivo and inhibition of 
calcineurin could provoke accumulation of pTDP in mammals. To test this hypothesis, we 
treated HEK293 cells with the calcineurin inhibitor FK506. FK506 binds the immunophilin 
FKBP12, forming a drug-immunophilin complex that interacts with and inhibits calcineurin 
activity [36]. Cells were incubated with FK506, followed by induction of full-length 
phosphorylated TDP-43 using a chemical trigger, ethacrynic acid [21]. We observed a dose-
dependent increase in pTDP with calcineurin inhibition (Fig. 4a-b). Interestingly, levels of 
total TDP-43 remain constant, perhaps due to the relatively rapid experimental time course. 
To determine whether FK506 treatment results in accumulation of detergent insoluble pTDP, 
we performed a sequential extraction using buffers with increasing solubilizing strengths 
[Low Salt< Triton x-100< Sarkosyl< Urea]. We find that pTDP is present in all fractions 
including both soluble and sarkosyl-insoluble fractions (Fig. 4c).
Cell immunofluorescence following FK506 treatment and ethacrynic acid induction of 
pTDP shows increased pTDP staining compared to control cells (Fig. 4d-l). This pTDP 
staining is distributed throughout the cytoplasm and nucleus, and includes areas of higher 
intensity staining that may represent pre-aggregates.
Cells incubated with FK506 in the absence of ethacrynic acid accumulated a lower 
molecular weight 35kDa pTDP species (TDP-35) detectable by immunoblot (Supplemental 
Fig. 3a). TDP-35 has been previously observed in human disease, and has been 
demonstrated to promote aggregation and recruit TDP-43 into inclusions [8, 9, 22]. To 
determine whether activation of calcineurin is protective, we treated HEK293 cells with the 
metal ion Ni2+. Ni2+ is a robust calmodulin-independent activator of calcineurin in vitro and 
in vivo [28, 48, 51]. Incubating HEK293 cells with Ni2+ treatment resulted in clearance of 
pTDP-35 (Supplementary Fig. 3b), indicating that increased calcineurin activity can 
decrease pTDP species. Taken together, our data suggest calcineurin dephosphorylates 
TDP-43 in human cultured cells, and inhibition of calcineurin activity allows pTDP to 
accumulate under conditions of cellular stress.
Accumulation of pTDP may cause changes in gene expression or splicing profiles of 
TDP-43 regulated genes. We tested whether the expression of HDAC6, a TDP-43 regulatory 
target [27], changed following FK506 treatment. However, we did not see any significant 
alteration of HDAC6 expression as measured by quantitative reverse transcription PCR 
(qRT-PCR) (Supplemental Fig. 3c). We also evaluated splicing in TDP-43 target genes 
POLDIP3/SKAR, STAG2, and FNIP1 [11, 14, 55], but found no changes in their respective 
splicing profiles (Supplemental Fig. 3c). Thus pTDP accumulation observed following 
FK506 treatment does not appear to alter TDP-43 splicing functions for multiple known 
target genes.
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Calcineurin co-localizes with pTDP-positive inclusions in FTLD-TDP and ALS
Calcineurin is a highly expressed neuronal phosphatase present in many regions of the brain, 
including the hippocampus and cerebral cortex [49]. To determine whether changes in 
calcineurin distribution pattern or localization were apparent in disease affected brain 
regions containing pTDP aggregates, we immunostained tissue from patients with FTLD-
TDP and unaffected controls (normal, NL) (Fig. 5 and Table 1). We observed similar 
distributions of calcineurin in the hippocampus and frontal cortex in both FTLD-TDP and 
control tissue. In the hippocampus, calcineurin was abundant in the dentate granule cells as 
well as CA pyramidal neurons, while in the frontal cortex, calcineurin immunoreactivity was 
most prominent in cortical layers II, IV, and VI (Fig. 5). FTLD-TDP cases and unaffected 
controls were qualitatively ranked for staining intensity in cortical layers II, IV, and VI 
(Table 2). In both cases and controls calcineurin staining was consistent in cortical layers II 
and VI. Interestingly, in cortical layer IV, calcineurin staining was mild (N=3) or 
undetectable (N=5) in all of the controls evaluated. However, calcineurin staining was 
detected in cortical layer IV in all FTLD-TDP cases evaluated. In FTLD-TDP cases, layer 
IV staining was ranked as moderate (N=8) or robust (N=1), with only one case ranked as 
mild. It is possible that increased calcineurin expression in FTLD-TDP cases is protective 
for neurons in cortical layer IV, as these neurons are typically spared pTDP pathology and 
neurodegeneration in FTLD-TDP.
FTLD-TDP affected hippocampal and cerebral cortical regions rich in pTDP deposition 
were robustly immunoreactive for calcineurin (Fig. 6a-f). To evaluate whether calcineurin is 
co-expressed in neurons with pTDP aggregates, we performed double-label 
immunohistochemistry for calcineurin and pTDP. We observed co-expression of calcineurin 
in cells bearing pTDP-positive lesions in hippocampal dentate granule cells, CA1 pyramidal 
cells, and frontal cortex layer II (Fig. 6g-i). Motor neurons accumulate pTDP aggregates in 
ALS. To assess whether calcineurin is co-expressed with pTDP in disease affected spinal 
cord motor neurons, we performed double-label immunohistochemistry for calcineurin and 
pTDP. We found that calcineurin and pTDP staining also overlaps in these cells in 
cytoplasmic aggregates (Fig. 6j). We did not observe calcineurin and pTDP co-localizaed in 
dystrophic neurites. To confirm co-localization of calcineurin and pTDP, we performed 
double-label immunofluorescence for calcineurin and pTDP in FTLD-TDP hippocampal 
dentate granule cells (Fig. 7, Supplemental Fig. 4) and frontal cortex layer II (Fig. 8, 
Supplemental Fig. 5). We observed significant co-localization of calcineurin with pTDP-
positive cytoplasmic aggregates in both brain regions in FTLD-TDP cases (Fig. 7d-e; Fig. 
8d-e). We also performed double-label immunofluorescence for calcineurin and pTDP on 
spinal cord sections from ALS patients (Fig. 9 and Supplemental Fig. 7). In these neurons, 
calcineurin and pTDP proteins are abundant and significantly co-localize. The co-occurrence 
of pTDP and calcineurin in neurons of degenerating regions is consistent with a role for 
calcineurin regulation of pTDP accumulation in ALS and FTLD-TDP.
Discussion
We have demonstrated that the phosphatase calcineurin can directly interact with and 
dephosphorylate TDP-43. This is the first report of a phosphatase with specificity for 
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pS409/410 TDP-43. Our data indicate regulation of TDP-43 phosphorylation is critical to 
maintaining neuronal function and viability. We have shown purified recombinant human 
calcineurin catalyzes dephosphorylation of purified human pTDP in vitro. In a C. elegans 
model of TDP-43 proteinopathy, genetic loss of calcineurin function dramatically worsens 
motor phenotypes, pTDP accumulation, and neurodegeneration. In mammalian cell culture, 
pharmacological inhibition of calcineurin drives accumulation of phosphorylated TDP-43, 
indicating calcineurin has a conserved role in regulating pTDP. In disease affected brain 
regions from patients with FTLDTDP, we observe overlap and co-localization of calcineurin 
protein and pTDP-positive lesions in both the frontal cortex and hippocampus. We observe a 
similar co-localization of calcineurin and pTDP in spinal cord motor neurons from patients 
with ALS. The results presented here suggest calcineurin activity catalyzes the conversion of 
pathological pTDP back to normal non-phosphorylated TDP-43.
TDP-43 phosphorylation may be a regulated cellular event balanced by the activities of 
specific kinases and phosphatases. While pTDP is not detected in normal human brain, it is 
possible that it is transiently produced at low levels and rapidly dephosphorylated. We do 
observe a low level of 35kDa pTDP in HEK293 cells under normal culture conditions 
(Supplementary Fig. 3b). pTDP may influence aspects of TDP-43 protein metabolism or 
function, possibly in response to specific or general cellular stresses. While the endogenous 
or environmental triggers of neuronal TDP-43 phosphorylation remain unclear, in 
mammalian cell culture full-length pTDP is induced under conditions of oxidative stress [21, 
26]. If cellular homeostasis is disrupted, an imbalance between phosphate addition and 
removal on TDP-43 could lead to accumulation of pTDP and subsequent neurotoxicity (Fig. 
10). This hypothesis is consistent with our data showing Ni2+ mediated activation of 
calcineurin decreases endogenous pTDP-35 present in HEK293 cells (Supplementary Fig. 
3b).
Our hypothesis is supported by another neuropathological observation: while calcineurin 
staining intensity appeared consistent between FTLD-TDP cases and controls in cortical 
layers II and VI, staining in cortical layer IV was stronger in patients than in controls. Layer 
IV is typically spared TDP-43 pathology and neuronal loss in FTLD-TDP. It is possible that 
upregulation of calcineurin in these neurons protects against the accumulation of pTDP.
This study demonstrates normal calcineurin activity antagonizes the activity of TDP-43 
kinases. Taken together our data have potentially clinically relevant implications. 
Calcineurin inhibitors have clinical utility as immunosuppressant drugs to prevent 
transplanted organ rejection [38]. Clearly calcineurin inhibition on its own does not trigger 
ALS or other TDP-43 proteinopathies in treated patients. However, lymphocytes from 
patients with ALS have decreased calcineurin activity levels compared to controls [13], 
perhaps indicating changes in calcineurin activity are playing a role in the genesis or 
progression of disease. A subset of patients who have received calcineurin inhibitors 
following organ transplant have adverse neurological and psychological effects, including 
tremor, neuralgia, peripheral neuropathy, psychosis, hallucinations, seizures, cerebellar 
ataxia, motor weakness, or reversible encephalopathy [60]. In some cases, neurotoxic 
symptoms persist after discontinuation of calcineurin inhibitors [12]. Suppressing 
calcineurin activity may unmask latent TDP-43 proteinopathy or exacerbate progression of 
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TDP-43 pathology in TDP-43 proteinopathy patients. The relationship between calcineurin 
inhibitor use and TDP-43 proteinopathy warrants further study. Calcineurin inhibitors have 
been proposed as a therapeutic strategy for ALS on the basis of immunosuppressive/anti-
neuroinflammatory mechanisms, and a clinical trial using FK506 in ALS has been initiated 
[16]. Our data demonstrate that calcineurin inhibition can trigger pTDP accumulation in 
some contexts, and suggest caution should be taken in these approaches to therapy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Calcineurin interacts with and dephosphorylates TDP-43. (a) Full length human TDP-43 
contains both nuclear localization (NLS) and export (NES) signals, RNA recognition motifs 
(RRM), and a C-terminal G-rich domain. The portion of TDP-43 used as bait in the yeast 
two-hybrid assay, amino acids 260-414, is depicted below. (b) Wild-type TDP-43 (TDP-43) 
and fALS-mutants A315T TDP-43 (A315T) and M337V TDP-43 (M337V) were assayed 
for interaction with calcineurin A/ PPP3CC. Serial dilutions of transformed colonies were 
plated on selective media to assay specificity and the relative strength of interactions. The 
bacteriophage coat protein MS2 was used as a negative control for calcineurin binding. (c) A 
time dependent decrease in pTDP is observed in an in vitro dephosphorylation assay. Full-
length recombinant hyperphosphorylated TDP-43 was incubated in the presence (+) or 
absence (−) of purified calcineurin for the indicated length of time, up to 60 minutes. pTDP 
is detected by immunoblotting with a phospho-S409/410 pTDP specific antibody. 
Calcineurin and total TDP-43 immunoblots are included to demonstrate load and protein 
stability during the course of the experiment.
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Fig. 2. 
The C. elegans calcineurin A homolog, tax-6, regulates TDP-43 phosphorylation in vivo. (a) 
Two different tax-6 loss of function alleles, p675 and ok2065, increase phosphorylation 
(pTDP) and total protein levels of WT TDP-43 transgenic C. elegans. (b) Bar graphs 
represent measurement of 3 independent replicate immunoblots. Significance was evaluated 
using one-way analysis of variance with Tukey’s multiple comparison test among 
TDP-43(WT), TDP-43(WT); tax-6(p675), and TDP-43(WT); tax-6(ok2065). p=0.001 
comparing relative pTDP band intensities. p=0.005 comparing relative total TDP-43 band 
intensities. (c) tax-6 loss of function alleles increase pTDP and total TDP in A315T TDP-43 
transgenic C. elegans. (d) Bar graphs represent measurement of 4 independent replicate 
immunoblots. Significance was evaluated using one-way analysis of variance with Tukey’s 
multiple comparison test among TDP-43(A315T), TDP-43(A315T); tax-6(p675), and 
TDP-43(A315T); tax-6(ok2065). p=0.008 comparing relative pTDP band intensities. 
p=0.0002 comparing total TDP-43 band intensities. (e) TDP-43(A315T) and 
TDP-43(A315T); tax-6(ok2065) were subjected to sequential protein extraction with 
detergents of increasing solubilizing strengths. Levels of sarkosyl-insoluble (SARK) 
TDP-43 and pTDP are increased with loss of tax-6. (f) tax-6(ok2065) increases levels of 
total TDP-43 in non-phosphorylatable TDP-43(M337V SS/AA); tax-6(ok2065). (g) Bar 
graphs represent measurement of 4 independent replicate immunoblots. Significance was 
evaluated using Student’s t-test between TDP-43(M337V SS/AA) and TDP-43(M337V SS/
AA); tax-6(p675), p=0.0002. (h-i) Calcineurin loss of function significantly worsens 
TDP-43 tg motor dysfunction. Dispersal velocity of developmentally staged L4 larvae was 
measured by calculating the radial distance traveled from a designated central starting point 
over 30 minutes. (h) N=166 for TDP-43(WT), N=144 for TDP-43(WT); tax-6(p675), N=149 
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for TDP-43(WT); tax-6(ok2065). Significance was evaluated using one-way analysis of 
variance with Tukey’s multiple comparison test among TDP-43(WT), TDP-43(WT); 
tax-6(p675), and TDP-43(WT); tax-6(ok2065). p<0.0001 versus TDP-43(WT). (i) N=364 
for TDP-43(A315T), N=177 for TDP-43(A315T); tax-6(p675), N=140 for TDP-43(A315T); 
tax-6(ok2065). Significance was evaluated using one-way analysis of variance with Tukey’s 
multiple comparison test among TDP-43(A315T), TDP-43(A315T); tax-6(p675), and 
TDP-43(A315T); tax-6(ok2065). p<0.0001 versus TDP-43(A315T). (j) TDP-43(M337V) 
with mutations of serines 409/410 to non-phosphorylatable alanines (SS/AA) do not exhibit 
exacerbated motor phenotypes with calcineurin loss of function. N=210 for TDP-43(M337V 
SS/AA), N=118 for TDP-43(M337V SS/AA); tax-6(ok2065). Significance was evaluated 
using Student’s t-test between TDP-43(M337V SS/AA) and TDP-43(M337V SS/AA); 
tax-6(ok2065). n.s. is not significant.
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Fig. 3. 
Loss of calcineurin function promotes TDP-43 dependent neurodegeneration. (a) GFP-
labeled D-type GABAergic motor neurons were counted at day 1 of adulthood in vivo in 
living worms. tax-6(ok2065) had an average of 0.3 neurons lost out of a normal potential 
complement of 19 total (13VD + 6DD type neurons) (N=25). TDP-43(M337V SS/AA) 
averaged 0.2 neurons lost per animal (N=30), TDP-43(M337V SS/AA); tax-6(ok2065) 
averaged 0.2 (N=29), TDP-43(WT) averaged 0.6 (N=32), TDP-43(WT); tax-6(ok2065) 
averaged 1.5 (N=30), TDP-43(A315T) averaged 2.2 (N=25), and TDP-43(A315T); 
tax-6(ok2065) animals averaged 6.8 neurons lost (N=22). Significance was evaluated using 
one-way analysis of variance with Tukey’s multiple comparison test among strains tested. 
n.s. is not significant. **p<0.05. ***p<0.0001. (b-d) GFP fluorescence images of 
GABAergic motor neurons. Neuron cell bodies are marked with asterisks. Animals are 
oriented with head left and ventral down. (b) tax-6(ok2065), (c) TDP-43(WT), (d) 
TDP-43(WT); tax-6(ok2065), (e) TDP-43(A315T), (f) TDP-43(A315T); tax-6(ok2065).
Liachko et al. Page 20
Acta Neuropathol. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 4. 
Calcineurin regulates TDP-43 phosphorylation in mammalian cells. (a) HEK293 cells show 
a dose-dependent increase in full-length pTDP following treatment with the calcineurin 
inhibitor FK506 and induction of pTDP with a chemical trigger. Cells were treated with the 
indicated concentrations of the calcineurin inhibitor FK506 for 1.5 hours, followed by 
induction of phosphorylated TDP-43 with 150μM ethacrynic acid (EA) for 3 hours. pTDP 
and TDP-43 were detected by immunoblot. (b) Bar graphs represent measurement of 3 
independent replicate immunoblots for pTDP and total TDP-43. Significance was evaluated 
using repeated measures analysis of variance with Dunnett’s multiple comparison test. 
**p=0.0342 comparing control treated cells versus 25μM FK506 treated cells. (c) HEK293 
cells treated with EA or EA/FK506 were subjected to sequential protein extraction with 
detergents of increasing solubilizing strengths, and immunoblotted for pTDP and total 
TDP-43. pTDP and total TDP-43 are present in both soluble (low salt buffer (LS) soluble) 
and insoluble (sarkosyl-insoluble (SARK)) protein fractions. (d-f) Control HEK293 cells 
immunostained for pTDP have minimal pTDP immunoreactivity. (g-i) HEK293 cells treated 
with EA have moderate pTDP immunoreactivity. (j-l) HEK293 cells treated with FK506 to 
inhibit calcineurin prior to EA treatment have strong pTDP immunoreactivity throughout the 
cytoplasm and nucleus. DAPI staining (d,g,j) indicates the nucleus. pTDP staining (e,h,k). 
Merge of DAPI (blue) and pTDP (red) staining (f,i,l).
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Fig. 5. 
Calcineurin distribution in the hippocampus and frontal cortex is similar in FTLDTDP and 
normal subjects. Representative photomicrographs depicting calcineurin immunoreactivity 
in the dentate gyrus (a,b), hippocampal CA1 field (c,d), and frontal cortex (e,f) of a normal 
control subject (a,c,e) and a subject with FTLD-TDP (b,d,f). Scale bar: 250 μm.
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Fig. 6. 
Calcineurin is expressed in brain regions exhibiting pTDP pathology, and co-expressed with 
pTDP pathology. Representative photomicrographs depicting pTDP (a,d) and calcineurin 
(b,c,e,f) in the hippocampal dentate granule cells (DGC) (a,b,c) and layer II of the frontal 
cortex (d,e,f) in an FTLD-TDP (a,b,d,e) and a normal (c,f) case. The distribution of pTDP 
immunoreactivity in the hippocampus and cortex of the FTLD case overlaps calcineurin 
(a,b,d,e). The distribution of calcineurin immunoreactivity in normal and FTLD-TDP cases 
appears similar (b,c,e,f). Scale bars: 50 μm. Calcineurin (brown) is co-expressed with pTDP 
(black) in (g) hippocampal dentate granule cells (DGC), (h) hippocampal CA1 pyramidal 
neurons (CA1), (i) cortical neurons (Ctx), and (j) ALS spinal cord motor neurons (SC). 
Scale bars: 25 μm.
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Fig. 7. 
Calcineurin co-localizes with pTDP pathology in FTLD-TDP hippocampus. 
Immunofluorescence of (a) DAPI, (b) calcineurin, (c) pTDP. (d) Merge image of DAPI, 
calcineurin, and pTDP immunofluorescence. (e) Plot of pTDP and calcineurin colocalization 
(Pearson’s coefficient of correlation = 0.9527).
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Fig. 8. 
Calcineurin co-localizes with pTDP pathology in FTLD-TDP frontal cortex. 
Immunofluorescence of (a) DAPI, (b) calcineurin, (c) pTDP. (d) Merge image of DAPI, 
calcineurin, and pTDP immunofluorescence. (e) Plot of pTDP and calcineurin colocalization 
(Pearson’s coefficient of correlation = 0.9328).
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Fig. 9. 
Calcineurin co-localizes with pTDP pathology in ALS spinal cord motor neurons. 
Immunofluorescence of (a) DAPI, (b) calcineurin, (c) pTDP. (d) Merge image of DAPI, 
calcineurin, and pTDP immunofluorescence. (e) Plot of pTDP and calcineurin colocalization 
(Pearson’s coefficient of correlation = 0.9779).
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Fig. 10. 
Calcineurin protects against the accumulation of neurotoxic pTDP. (a) Under normal cellular 
conditions, low levels of pTDP are generated and rapidly cleared through the action of the 
phosphatase calcineurin. (b) During an acute cellular stress or following dysregulation or 
inhibition of calcineurin, the balance between non-phosphorylated and phosphorylated 
TDP-43 is shifted towards production of pTDP, leading to neuronal dysfunction and eventual 
cell death.
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Table 1
Clinical details from evaluated FTLD-TDP cases
Type FamilyHistory Mutation Sex Age Onset Duration
Brain
Weight (g)
A + F 64 59 5 880
A + M 68 62 6 1040
A + GRN M 69 62 7 1000
B U F 58 U U 1110
B + F 54 49 5 1100
B − F 85 82 3 980
B − M 49 44 5 1188
B U M 67 61 6 1140
C − F 65 53 12 990
C + F 81 68 13 1040
Age age at death, Duration length of disease course, Family History other affected family members with FTLD-TDP, GRN progranulin gene, 
Mutation identified genetic cause of FTLD-TDP, Onset age at diagnosis of FTLD, Type harmonized FTLD-TDP classification [37], U unknown, + 
positive, − negative
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Table 2
Ranking of calcineurin immunostaining
Controls
Layer
II
Layer
IV
Layer
VI
M ND M
R L R
R L R
M ND M
M L M
L ND L
M ND L
M ND M
FTLD-TDP Cases
Layer
II
Layer
IV
Layer
VI
M M M
R M R
L R M
R M R
R M R
M M M
M M M
R M R
M M M
M L M
Layer cortical layer, L mild, M moderate, ND not detected, R robust
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